Lilly’s Q4 Growth Came From More Than Just Tirzepatide
Mounjaro and Zepbound led Lilly’s 45% sales increase, but non-incretin products such as Verzenio and Taltz helped produce 20% growth outside of the incretin portfolio.
Mounjaro and Zepbound led Lilly’s 45% sales increase, but non-incretin products such as Verzenio and Taltz helped produce 20% growth outside of the incretin portfolio.